Cargando…

Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review

Objective: The effects of rotigotine transdermal patch (RTG) on the neuropsychiatric symptoms of Parkinson's disease (PD) outcomes remain controversial. The aim of this review was to determine the efficacy and safety of RTG on the neuropsychiatric symptoms of PD. Methods: In this systematic rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Junqiang, Ma, Hongxia, Liu, Anran, Huang, Jiarui, Wu, Jiannan, Yang, Jianxue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567083/ https://www.ncbi.nlm.nih.gov/pubmed/34744967 http://dx.doi.org/10.3389/fneur.2021.722892

Ejemplares similares

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

A Study for Expanding Application Sites for Rotigotine Transdermal Patch
por: Kujirai, Hitoshi, et al.
Publicado: (2020)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review
por: Yan, Junqiang, et al.
Publicado: (2021)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
por: Elshoff, Jan-Peer, et al.
Publicado: (2015)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists
por: Ikeda, Ken, et al.
Publicado: (2016)

Delirious episode secondary to rotigotine: the psychotic patch
por: Andreo Vidal, M. A., et al.
Publicado: (2023)

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis
por: Sun, Wenjie, et al.
Publicado: (2022)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study
por: Pagonabarraga, Javier, et al.
Publicado: (2015)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015)

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD
por: Castrioto, A., et al.
Publicado: (2020)

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Publicado: (2016)

Neuropsychiatric Symptoms in Parkinson's Disease After Subthalamic Nucleus Deep Brain Stimulation
por: Liu, Weibing, et al.
Publicado: (2021)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

Preventive effect of a heparinoid-containing product on the application site reaction of the rotigotine transdermal patch in Parkinson’s disease: A pilot randomized clinical trial (the SkinHeRo study)
por: Koh, Jinsoo, et al.
Publicado: (2021)

Atorvastatin improves motor function, anxiety and depression by NOX2-mediated autophagy and oxidative stress in MPTP-lesioned mice
por: Yan, Junqiang, et al.
Publicado: (2020)

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial
por: Schurad, Bjoern, et al.
Publicado: (2022)

Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
por: Iravani, Behnam, et al.
Publicado: (2022)

Effect of statins on Parkinson's disease: A systematic review and meta-analysis
por: Yan, Junqiang, et al.
Publicado: (2019)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Editorial: Neuroimaging of Cognitive and Neuropsychiatric Symptoms in Movement Disorders
por: Sampedro, Frederic, et al.
Publicado: (2022)

Levodopa/rotigotine: Lack of efficacy: case report
Publicado: (2022)

Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
por: Schmitt, Emmanuelle, et al.
Publicado: (2023)

Dropped head sign induced by transdermal application of the dopamine agonist rotigotine in parkinsonian syndrome: a case report
por: Dohm, Christoph P, et al.
Publicado: (2013)

Neuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literature
por: Macías-García, Paloma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9b6jv3uvg66rqvmnjiupb1hukr